Skip to main content
Past Event Sticker

Adverse Drug Events (ADE): Sprint for Improvement Session 5. Opportunities to Improve the Use of Oral Anticoagulants

Young Female Doctor Business Audience

Tuesday, August 8, 2017, 12:30 p.m. to 1:30 p.m. PT.

This fast-paced series of 8 virtual learning sessions begins May 23, 2017. One continuing Education credit from the California Board of Registered Nursing is offered for each session. The sessions will be held biweekly. There is no cost to attend.

This Sprint Series will:

  • Quickly and efficiently drive ADE data reporting by as many hospitals as possible through education about the ADE measures and strategies for data abstraction.
  • Facilitate rapid improvement across all three ADE subtopics. 
  • Provide a task-based action plan for hospitals to implement that encourages sustainable, reliable improvement in ADE. 
  • Increase the capacity for improvement by targeting multiple disciplines in this work with basic and advanced performance improvement skills training. 

Download the Presentation

Download the Recording

Webinar Objectives:

At the end of the educational activity, attendees will be able to:

  • Describe the public health significance of anticoagulant adverse drug events (ADEs).
  • Describe the role of anticoagulants in preventing thromboembolic disease.
  • Compare characteristics of warfarin and direct oral anticoagulants (DOACs).
  • Discuss opportunities to improve use of oral anticoagulants.


Christopher St. Clair, PharmD
ORISE Health Care Quality Fellow
Division of Health Care Quality
Office of Disease Prevention and Health Promotion
Office of the Assistant Secretary for Health
U.S. Department of Health and Human Services

Mary Andrawis, PharmD, MPH
Executive Director, Medication Safety and Quality, Health Services Advisory Group (HSAG)

Save these dates! Future sessions, 12:30-1:30 p.m. (PT):
Session 6: August 17. Strategies to Accelerate Improvement in Opioid Safety
Session 7: September 19. Glycemic Control 
Session 8: October 3. Engaging Patients and Family Members in the Reduction of ADEs